Skip to main content
OCUL logo

OCUL · Ocular Therapeutix, Inc

Track OCUL — free
$5.93 -0.02 (-0.25%)
Market Cap
$1.31B
Shares
220.02M
Volume · Nov 19 133.3K Avg daily vol (3M) 3.04M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.94 Open$6.05 Day$5.92–6.35 52W close$5.94–16.11 Avg vol 30d3.0M Short int29.0M · 13.2% of shares · 10.1d Short vol26% Last earningsNov 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 17
Investor event
X-Paxly Phase III shows superiority over anti-VEGF

Ocular Therapeutics said its Phase III trial of X-Paxly showed superiority over an anti-VEGF with a p-value of less than 0.0006. The company expects to submit the NDA in the fourth quarter of this year. It also moved the SOL-R primary endpoint to week 40 from week 56.

4 source passages
We have a result that has a very robust p-value of less than 0.0006 We hit a superiority endpoint against a very, very good drug in ILEA with a robust p-value we would be submitting the NDA in the fourth quarter of this year the change was you moved the primary endpoint up to week 40 from week 56 Open the document at this passage
Nov 9
Earnings call
X-Paxley NDA on track; SOLAR endpoint moved to week 40

Ocular remains on track to submit X-Paxley’s wet AMD NDA in the fourth quarter and moved SOLAR’s primary endpoint from week 56 to week 40, preserving trial integrity. It ended the third quarter with $530.6 million in cash.

6 source passages
our investigational product candidate, X-Paxley, also known as OTX-TKI, which is in development for wet age-related macular degeneration and non-proliferative diabetic retinopathy our highest near-term priority remains the planned submission of our NDA for XPACSLE and wet AMD in the fourth quarter of this year we proactively initiated a process in May after our type C meeting with the FDA to move the primary endpoint from week 56 to week 40 This change ensures all patients will have completed their primary efficacy assessments before the planned interim safety analysis. We ended the third quarter with $530.6 million in cash and cash equivalents Ocular Therapeutics Open the document at this passage
Nov 9
Current report 8-K Events of Nov 6
Riad Sherif joins board as Seung Suh Hong resigns

Ocular Therapeutix elected Riad Sherif to its Board effective November 6, 2026, as a Class I director until the 2027 annual meeting. Seung Suh Hong resigned effective December 31, 2026, with no disagreement over operations, policies or practices.

Director or officer change, or executive pay
4 source passages
On November 6, 2026, the Board of Directors (the “Board”) of Ocular Therapeutix, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately. Dr. Sherif was designated as a Class I member of the Board to serve until the Company’s 2027 annual meeting of stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation or removal. On November 6, 2026, Seung Suh Hong, Ph.D., notified the Company of his resignation from the Board, effective December 31, 2026. Dr. Hong’s resignation is not the result of any disagreement with the Board or with management on any matter relating to the Company’s operations, policies or practices. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
AXPAXLI meets SOL-1 primary and key secondary endpoints

Ocular Therapeutix said AXPAXLI met SOL-1’s Week 36 primary endpoint, with 74.1% maintaining visual acuity versus 55.8% for aflibercept 2 mg. At Week 52, 65.9% maintained visual acuity versus 44.2%.

Revenue $12.87M ▼ 11.5% Net loss $94.78M Diluted EPS -$0.42
Read from the MD&A section
3 source passages
In February 2026, we announced positive topline Week 52 results for the SOL-1 trial. AXPAXLI met its primary endpoint with statistical significance. The proportion of subjects who maintained visual acuity, defined as a loss of fewer than 15 Early Treatment of Diabetic Retinopathy Study, or ETDRS, letters from baseline, at Week 36 was 74.1% in the AXPAXLI arm compared to 55.8% in the aflibercept 2 mg arm, with a risk difference of 17.5% and a p-value of 0.0006 per the pre-specified statistical model, and with an observed difference of 18.3%. The proportion of subjects who maintained vision at Week 52 was 65.9% in the AXPAXLI arm compared to 44.2% in the aflibercept 2 mg arm, with a risk difference of 21.1%, and a p-value of <0.0001 per the pre-specified statistical model compared to aflibercept 2 mg subjects, and with an observed difference of 21.7%. Open the document at this passage
Nov 9
Current report 8-K
AXPAXLI wet AMD NDA submission on track for 4Q 2026

Ocular Therapeutix, Inc. said its AXPAXLI wet AMD NDA submission remains on track for 4Q 2026 under 505(b)(2), with $530.6 million cash and expected runway into 2028. Third-quarter revenue was $12.9 million and net loss was $(94.8) million.

Financial results
6 source passages
Following completion of positive Pre-NDA Meeting in September 2026, AXPAXLI New Drug Application (NDA) submission on track for 4Q 2026. Ocular intends to submit the AXPAXLI NDA under the 505(b)(2) regulatory pathway Total cash and cash equivalents were $530.6 million as of September 30, 2026. the Company believes that its current cash balance is sufficient to support its planned operating expenses, debt service obligations and capital expenditure requirements into 2028. Total net revenue was $12.9 million for the third quarter of 2026, compared with $14.5 million for the comparable quarter of 2025. Net loss for the third quarter of 2026 was $(94.8) million, or a net loss of $(0.42) per share on both a basic and diluted basis, compared with a net loss of $(69.4) million, or a net loss of $(0.38) per share on a basic and diluted basis, for the comparable quarter of 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$50.38M
Trailing 12 months
Net income (TTM)
−$326.81M
Trailing 12 months
Revenue growth YoY
-11.5%
Year over year
Operating margin
-680.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-20.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$457.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+22.6%
Year over year · more shares
Price change (1Y)
-49.5%
Trailing year
Short interest
13.2%
Latest settlement · 10.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. AXPAXLI’s wet AMD NDA remains on track for 4Q 2026 with FDA alignment, and the 505(b)(2) pathway could shorten review by up to 60 days. SOL-1 demonstrated superiority, SOL-R’s Week 40 endpoint change preserves trial integrity, and SOL-X will evaluate 48-week dosing. Revenue declined, operating expenses increased, and net loss widened; cash provides a runway into 2028 but excludes full manufacturing scale-up and commercial-team costs if AXPAXLI is approved.

Bullish
  • + SOL-1 met its superiority primary endpoint, with 74.1% of AXPAXLI-treated subjects maintaining vision at Week 36.
  • + SOL-1 post hoc analysis showed sustained anatomical control, with approximately 70% of subjects who were dry at Week 8 remaining dry through Week 36 after one injection.
  • + SOL-R’s primary endpoint was moved to Week 40 so all subjects could complete efficacy assessments before the Week 52 interim safety analysis, preserving trial integrity.
  • + Ocular plans to modify SOL-X to evaluate AXPAXLI dosing every 48 weeks based on demonstrated durability.
Bearish
  • − Research and development expense increased to $74.8 million from $52.4 million, driven by faster enrollment and expanded clinical infrastructure.
  • − The cash-runway projection excludes the full costs of manufacturing scale-up and commercial staffing if AXPAXLI is approved.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −23%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −34%
trailing
YTD return −51%
this year
Relative strength −31%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +39 funds added
Insider flow Distributing
Net -$11.3K over 90 days · 100% sells
Short interest Rising
13.18% of shares out · ▲ +0.8% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
266 holders — mid 3-yr range
Squeeze score 73
high risk · 0–100
Fundamentals
Weak
Revenue growth +3%
Y/Y
EPS growth −16%
Y/Y
Free cash flow $-216.9M
Balance sheet $665.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −63%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−23% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +39 funds added
Insider flow Distributing
Net -$11.3K over 90 days · 100% sells
Short interest Rising
13.18% of shares out · ▲ +0.8% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
266 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6 Now $6 · 0% Range high $16
vs 200-day avg -33% vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Customer 1 43% Three Months Ended June 30, 2026 filing —
Customer 2 25% Three Months Ended June 30, 2026 filing —
Customer 3 6% Three Months Ended June 30, 2026 filing —
Direct research and development expenses for our products and product candidates 29.5M the three months ended June 30, 2026 filing —
GTN Provisions as a percentage of gross DEXTENZA product sales 55% the three months ended June 30, 2026 filing —
In-Market Sales 50,000 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OCUL
Ocular Therapeutix, Inc
this stock
$1.31B -51.1% +3.5% — 13.2%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
266
% held
96.0%
Net QoQ
+4.0M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
197
View
Short & Settlement
Short Interest Rising
Shares short
29.0M
Days to cover
10.1d
Change
+238.0K sh
View
Short Volume
Short vol %
26%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
41.3K
Value
$297.6K
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
44.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$11.3K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$52.0M
Net income (FY)
$-265.9M
EPS diluted
$-1.42
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
19

Ocular Therapeutics said its Phase III trial of X-Paxly showed superiority over an anti-VEGF with a p-value of less than 0.0006. The company expects to submit the NDA in the fourth quarter of this year. It also moved the SOL-R primary endpoint to week 40 from week 56.

View
Proposed Sales
Value
$231.8K
Shares
35.4K
Filed
Nov 5, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Ocular Therapeutix™ Reports Third…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
OCUL -10.8% -8.3% -34.1% -14.8% -51.1%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -6.9% -2.8% -30.6% -11.4% -58.2%
Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 269 filings 250 filers Visit website Investor relations